Citigroup’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Citigroup’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$930K	–	5798
2023 Q1	$930K	Buy	+25,000	New	+$1.12M	﹤0.01%	2616
2022 Q3	–	Sell	-25,000	Closed	-$1.68M	–	6485
2022 Q2	$1.68M	Buy	+25,000	New	+$1.59M	﹤0.01%	2235
2021 Q1	–	Sell	-12,300	Closed	-$2.7M	–	7645
2020 Q4	$2.7M	Buy	12,300 +500	+4%	+$108K	﹤0.01%	2575
2020 Q3	$1.96M	Hold	11,800	–	–	﹤0.01%	2666
2020 Q2	$1.35M	Hold	11,800	–	–	﹤0.01%	3231
2020 Q1	$907K	Sell	11,800 -8,000	-40%	-$717K	﹤0.01%	3285
2019 Q4	$2.55M	Buy	19,800 +2,700	+16%	+$260K	﹤0.01%	2735
2019 Q3	$1.33M	Sell	17,100 -1,200	-7%	-$113K	﹤0.01%	3316
2019 Q2	$1.89M	Buy	18,300 +5,200	+40%	+$405K	﹤0.01%	2929
2019 Q1	$960K	Buy	+13,100	New	+$891K	﹤0.01%	3438

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's MRTX Position: Q1 2024 in Review

Citigroup sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 61,961 shares — an estimated $3.64M sold.

Citigroup first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $15.3M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Citigroup reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 61,961 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.64M.
Citigroup first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
Citigroup's Mirati Therapeutics, Inc. Common Stock position peaked at $15.3M in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.